{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:56:45Z","timestamp":1786114605625,"version":"build-2736575974"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R41AI191979"],"award-info":[{"award-number":["R41AI191979"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R41AI192172"],"award-info":[{"award-number":["R41AI192172"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pluripotent stem cell (PSC)-based therapies hold the potential to unlock cures for numerous diseases, including, but not limited to, Parkinson\u2019s disease, macular degeneration, heart failure, type 1 diabetes, and cancer. Yet as protocols to differentiate PSCs into therapeutically useful cell types have progressed rapidly, immunological rejection remains a major barrier that may limit the widespread use of such PSC-based therapies. In recent years, strategies to genetically modify PSCs to prevent immunological rejection of the downstream cell product have become a point of emphasis. Here, we provide an immunological perspective on these strategies, discussing the breadth of rejection mechanisms that have been uncovered through decades of research and the relative simplicity of designing PSC immune evasion strategies to circumvent these mechanisms. We focus in particular on how these strategies apply to the treatment of type 1 diabetes.<\/jats:p>","DOI":"10.1093\/stcltm\/szag051","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:37:53Z","timestamp":1778153873000},"source":"Crossref","is-referenced-by-count":0,"title":["Guiding pluripotent stem cell therapies past the immune system"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-8847","authenticated-orcid":false,"given":"Hannah A","family":"Pizzato","sequence":"first","affiliation":[{"name":"Center for Advanced Molecular and Immunological Therapies, University of Arizona , Tucson, AZ 85724,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8377-7699","authenticated-orcid":false,"given":"Deepta","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Center for Advanced Molecular and Immunological Therapies, University of Arizona , Tucson, AZ 85724,","place":["United States"]},{"name":"Department of Immunobiology, University of Arizona College of Medicine , Tucson, AZ 85724,","place":["United States"]},{"name":"Department of Surgery, University of Arizona College of Medicine , Tucson, AZ 85724,","place":["United States"]},{"name":"BIO5 Institute, University of Arizona , Tucson, AZ 85724,","place":["United States"]},{"name":"University of Arizona Cancer Center , Tucson, AZ 85724,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2026080517163761900_szag051-B1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2004.08.020","article-title":"The acquired immune system: a vantage from beneath","volume":"21","author":"Hedrick","year":"2004","journal-title":"Immunity"},{"key":"2026080517163761900_szag051-B2","doi-asserted-by":"publisher","first-page":"a015461","DOI":"10.1101\/cshperspect.a015461","article-title":"Effector mechanisms of rejection","volume":"3","author":"Moreau","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026080517163761900_szag051-B3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000205478","article-title":"Iso-leuko-antibodies","volume":"20","author":"Dausset","year":"1958","journal-title":"Acta Haematol"},{"key":"2026080517163761900_szag051-B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF02986826","article-title":"Methods for the study of histocompatibility genes","volume":"49","author":"Snell","year":"1948","journal-title":"J Genet"},{"key":"2026080517163761900_szag051-B5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1126\/science.175.4019.273","article-title":"Histocompatibility-linked immune response genes","volume":"175","author":"Benacerraf","year":"1972","journal-title":"Science (1979)"},{"key":"2026080517163761900_szag051-B6","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1073\/pnas.1017015108","article-title":"Alloreactivity is limited by the endogenous peptide repertoire","volume":"108","author":"Morris","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026080517163761900_szag051-B7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s10393-007-0117-1","article-title":"The immune response of the Tasmanian devil (Sarcophilus harrisii) and devil facial tumour disease","volume":"4","author":"Woods","year":"2007","journal-title":"Ecohealth"},{"key":"2026080517163761900_szag051-B8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/icb\/icy118","article-title":"Two decades of the impact of Tasmanian devil facial tumor disease","volume":"58","author":"Woods","year":"2018","journal-title":"Integr Comp Biol"},{"key":"2026080517163761900_szag051-B9","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1073\/pnas.90.9.3913","article-title":"Mice lacking major histocompatibility complex class I and class II molecules","volume":"90","author":"Grusby","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026080517163761900_szag051-B10","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1002\/eji.1830231055","article-title":"Graft rejection by T cells not restricted by conventional major histocompatibility complex molecules","volume":"23","author":"Dierich","year":"1993","journal-title":"Eur J Immunol"},{"key":"2026080517163761900_szag051-B11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.smim.2015.03.010","article-title":"Viral immune evasion: lessons in MHC class I antigen presentation","volume":"27","author":"van de Weijer","year":"2015","journal-title":"Semin Immunol"},{"key":"2026080517163761900_szag051-B12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H \u2212 2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"K\u00e4rre","year":"1986","journal-title":"Nature"},{"key":"2026080517163761900_szag051-B13","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1681\/ASN.V10102208","article-title":"Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries","volume":"10","author":"Collins","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2026080517163761900_szag051-B14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nri1702","article-title":"Antibody-mediated organ-allograft rejection","volume":"5","author":"Colvin","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2026080517163761900_szag051-B15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1365-2249.1991.tb02954.x","article-title":"Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection","volume":"86","author":"Feucht","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"2026080517163761900_szag051-B16","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1096\/fj.13-246306","article-title":"Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4","volume":"28","author":"Asgari","year":"2014","journal-title":"FASEB J"},{"key":"2026080517163761900_szag051-B17","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/ajt.14262","article-title":"Complement alternative pathway deficiency in recipients protects kidney allograft from ischemia\/reperfusion injury and alloreactive T cell response","volume":"17","author":"Casiraghi","year":"2017","journal-title":"Am J Transplant"},{"key":"2026080517163761900_szag051-B18","doi-asserted-by":"publisher","first-page":"7523","DOI":"10.1073\/pnas.1101748108","article-title":"Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia\/reperfusion injury","volume":"108","author":"Schwaeble","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026080517163761900_szag051-B19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0002-9440(10)63839-4","article-title":"Role for the alternative complement pathway in ischemia\/reperfusion injury","volume":"162","author":"Stahl","year":"2003","journal-title":"Am J Pathol"},{"key":"2026080517163761900_szag051-B20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/ni831","article-title":"Cross-primed CD8+ T cells mediate graft rejection via a distinct effector pathway","volume":"3","author":"Valujskikh","year":"2002","journal-title":"Nat Immunol"},{"key":"2026080517163761900_szag051-B21","doi-asserted-by":"publisher","first-page":"10441","DOI":"10.1073\/pnas.1902566116","article-title":"Generation of hypoimmunogenic human pluripotent stem cells","volume":"116","author":"Han","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026080517163761900_szag051-B22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026080517163761900_szag051-B23","doi-asserted-by":"publisher","first-page":"e2022091118","DOI":"10.1073\/pnas.2022091118","article-title":"Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice","volume":"118","author":"Deuse","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026080517163761900_szag051-B24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41587-023-01784-x","article-title":"Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques","volume":"42","author":"Hu","year":"2024","journal-title":"Nat Biotechnol"},{"key":"2026080517163761900_szag051-B25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.stemcr.2023.12.003","article-title":"Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers","volume":"19","author":"Pizzato","year":"2024","journal-title":"Stem Cell Reports"},{"key":"2026080517163761900_szag051-B26","doi-asserted-by":"publisher","first-page":"1403395","DOI":"10.3389\/fgeed.2024.1403395","article-title":"CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice","volume":"6","author":"Frederiksen","year":"2024","journal-title":"Front Genome Ed"},{"key":"2026080517163761900_szag051-B27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41586-020-2631-z","article-title":"Immune-evasive human islet-like organoids ameliorate diabetes","volume":"586","author":"Yoshihara","year":"2020","journal-title":"Nature"},{"key":"2026080517163761900_szag051-B28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41551-023-01133-y","article-title":"Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts","volume":"8","author":"Harding","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"2026080517163761900_szag051-B29","doi-asserted-by":"publisher","first-page":"100879","DOI":"10.1016\/j.xcrm.2022.100879","article-title":"Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance","volume":"4","author":"Gerace","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026080517163761900_szag051-B30","doi-asserted-by":"publisher","first-page":"eadx9755","DOI":"10.1126\/sciadv.adx9755","article-title":"Human stem cell-derived \u03b2 cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes","volume":"11","author":"Brown","year":"2025","journal-title":"Sci Adv"},{"key":"2026080517163761900_szag051-B31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1399-3089.2007.00395.x","article-title":"Play it in E or G: utilization of HLA-E and -G in xenotransplantation","volume":"14","author":"Crew","year":"2007","journal-title":"Xenotransplantation"},{"key":"2026080517163761900_szag051-B32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1074-7613(02)00333-3","article-title":"The role of the NKG2D immunoreceptor in immune cell activation and natural killing","volume":"17","author":"Jamieson","year":"2002","journal-title":"Immunity"},{"key":"2026080517163761900_szag051-B33","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/bloodadvances.2024013436","article-title":"Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism","volume":"9","author":"Zhang","year":"2025","journal-title":"Blood Adv"},{"key":"2026080517163761900_szag051-B34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.bbrc.2011.12.025","article-title":"Identification of phosphatidylserine as a ligand for the CD300a immunoreceptor","volume":"417","author":"Nakahashi-Oda","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"2026080517163761900_szag051-B35","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/blood-2011-08-372425","article-title":"Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells","volume":"119","author":"Simhadri","year":"2012","journal-title":"Blood"},{"key":"2026080517163761900_szag051-B36","doi-asserted-by":"publisher","first-page":"e20200839","DOI":"10.1084\/jem.20200839","article-title":"The SIRP\u03b1\u2013CD47 immune checkpoint in NK cells","volume":"218","author":"Deuse","year":"2021","journal-title":"J Exp Med"},{"key":"2026080517163761900_szag051-B37","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41467-023-37785-2","article-title":"Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice","volume":"14","author":"Hu","year":"2023","journal-title":"Nat Commun"},{"key":"2026080517163761900_szag051-B38","doi-asserted-by":"publisher","first-page":"eadg5794","DOI":"10.1126\/scitranslmed.adg5794","article-title":"Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice","volume":"15","author":"Hu","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026080517163761900_szag051-B39","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/ni1008-1091","article-title":"The immunological genome project: networks of gene expression in immune cells","volume":"9","author":"Heng","year":"2008","journal-title":"Nat Immunol"},{"key":"2026080517163761900_szag051-B40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"2026080517163761900_szag051-B41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2201422","article-title":"Genetically modified porcine-to-human cardiac xenotransplantation","volume":"387","author":"Griffith","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080517163761900_szag051-B42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(23)00775-4","article-title":"Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report","volume":"402","author":"Mohiuddin","year":"2023","journal-title":"Lancet"},{"key":"2026080517163761900_szag051-B43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/TP.0000000000000252","article-title":"CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model","volume":"98","author":"Lin","year":"2014","journal-title":"Transplantation"},{"key":"2026080517163761900_szag051-B44","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.stem.2023.10.003","article-title":"Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity","volume":"30","author":"Gravina","year":"2023","journal-title":"Cell Stem Cell"},{"key":"2026080517163761900_szag051-B45","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41587-022-01540-7","article-title":"Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression","volume":"41","author":"Gravina","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2026080517163761900_szag051-B46","author":"Century Therapeutics","year":"2026"},{"key":"2026080517163761900_szag051-B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000547334","article-title":"Challenges and opportunities in the application of CRISPR-Cas9: a review on genomic editing and therapeutic potentials","volume":"35","author":"Karimi","year":"2026","journal-title":"Med Princ Pract"},{"key":"2026080517163761900_szag051-B48","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMc2516172","article-title":"Allogeneic beta cells with No immunosuppression","volume":"393","author":"Kumar","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080517163761900_szag051-B49","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.trecan.2025.06.003","article-title":"Beyond safety: suicide systems in cell-based cancer therapies","volume":"11","author":"Chen","year":"2025","journal-title":"Trends Cancer"},{"key":"2026080517163761900_szag051-B50","author":"Vertex Pharmaceuticals Incorporated","year":"2025"},{"key":"2026080517163761900_szag051-B51","author":"Vertex Pharmaceuticals Incorporated","year":"2025"},{"key":"2026080517163761900_szag051-B52","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1056\/NEJMoa2503822","article-title":"Survival of transplanted allogeneic beta cells with No immunosuppression","volume":"393","author":"Carlsson","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/8\/szag051\/70500187\/szag051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/8\/szag051\/70500187\/szag051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:16:50Z","timestamp":1785964610000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/doi\/10.1093\/stcltm\/szag051\/8752870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,20]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szag051","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,20]]},"article-number":"szag051"}}